-Illustrates the RanBP2/RanGAP1*SUMO1/Ubc9 complex variants that were tested for E3 ligase activity in addition to the ones in the result part. -Shows control experiments for the conjugation of the SUMO variants used.
Residues in the IR and SIM regions that were mutated to prevent Ubc9 and SUMO binding are in bold. (B) RanBP2 is responsible for sumoylation at nuclear pore complexes. Efficient knockdown of RanBP2 abolishes in situ sumoylation at the NPC. HeLa cells treated with siRNA against RanBP2 and untreated cells were mixed, permeabilized with digitonin and incubated in a sumoylation reaction with HeLa cytosol supplemented with YFP-SUMO1 in the presence or absence of ATP. After washing, samples were fixed, RanBP2 was immunostained with  RanBP2 antibodies, DNA was stained with Hoechst. The samples were analyzed by confocal microscopy. Reconstitution of RanBP2/RanGAP1*SUMO1/Ubc9 complexes resulted in two distinct pools that comigrated in gel filtration (not shown), but could be separated by ion exchange chromatography (MonoQ). Peak a eluted at 400 mM NaCl, peak b at 450 mM NaCl (panel A). Immunoblotting revealed that peak b contained more RanGAP1*SUMO1 and Ubc9 per molecule RanBP2 than peak a (panel B, e.g. compare lanes 1 and 2). A plausible interpretation was hence that two RanGAP1*SUMO1 and two Ubc9 molecules per RanBP2 can bind at the high protein concentrations used here. (C+D) SIM1 and IR1 are required for the formation of isopeptidase resistant RanBP2 complexes in vitro. To distinguish relevant from possibly irrelevant interactions, we took advantage of the fact that RanGAP1*SUMO1 is protected from demodification by isopeptidases in the endogenous RanBP2 complex. When we incubated wild type RanBP2 complex from peak a with Senp1, RanGAP1*SUMO1 was largely protected from desumoylation; in contrast, half of the RanGAP1*SUMO1 of peak b was rapidly cleaved (panel C, compare lanes 3 and 8) suggesting that only one of the associations leads to isopeptidase resistant interaction. Most striking was RanBP2 IR2mut, which gave rise to an isopeptidase resistant peak a, but not peak b. Mutating either SIM1 or IR1 motifs completely prevented formation of isopeptidase resistant complexes (see panel D for a time course of isopeptidase treatment; panel C, lanes 1-7 are identical to Fig 3B) . Sumoylation time courses for 640 nM YFP-Sp100 were performed either in standard assay buffer (20 mM HEPES pH 7.3, 110 mM KOAc, 2 mM Mg(OAc) 2 , 1 mM EGTA, 1 mM DTT, 0.05% Tween20, 0.2 mg/ml ovalbumin,1 µg/ml of each aprotinin, leupeptin, and pepstatin) or in modified assay buffer (20 mM PIPES pH 6.8, 150 mM NaCl, 1 mg/ml ovalbumin, 0.05% Tween20, 1 mM DTT, 1 µg/ml of each aprotinin, leupeptin, and pepstatin) in the presence of 107 nM E1, 56 nM Ubc9, 24 nM RanBP2 RB3-4 /RanGAP1*SUMO1/Ubc9 complex and 9 µM SUMO1. Immunoblot was quantified using IRDye-labeled secondary antibody and the LI-COR/Odyssey infrared imaging system (right panel). (A+B) Mutational analysis of additional recombinant RanBP2 complexes: 18 different complexes containing variants of RanBP2 RB3-4 , RanGAP1*SUMO1 or Ubc9 were purified using ion exchange and tested for stability against isopeptidase treatment and activity as described in the Result section. None of these was defective as E3 ligase suggesting that mutated residues were not critical for interaction with the Ubc9SUMO1 thioester. (B) IR1-M-IR2 region of RanBP2. Residues of IR1-M that have been shown to interact with Ubc9 and SUMO1 in the crystal structure (Reverter & Lima, 2005) and the homologous residues in IR2 are in red. Other colors illustrate the RanBP2 variants described in Figure S4A . (C) SUMO1 variants deficient in SIM interaction are efficiently conjugated to RanGAP1. Sumoylation time courses were performed in the presence of 1.6 µM RanGAP1, 18 nM E1, 14 nM Ubc9 and 3.9 µM SUMO1 without E3 ligase.
(D) SUMO1 variants deficient in SIM interaction are deficient in Sp100 conjugation with the RanBP2 complex, but are only slightly defective in conjugation with Ubc9 and E1. The slight defect is likely due to some contribution of the SIM in Sp100. Sumoylation time courses were performed in the presence of 840 nM GST-Sp100, 68 nM E1, 9 µM SUMO1 and either 56 nM Ubc9/24 nM RanBP2 RB3-4 complex (upper panel) or 560 nM Ubc9 without E3 ligase (lower panel). An  GST immunoblot is shown.
Supplemental Experimental Procedures Sumoylation in permeabilized cells
Detection of sumoylation activity in semi-permeabilized HeLa cells was carried out as described (Pichler et al., 2002) . In brief, cells transfected with siRNA against RanBP2 as described (Hutten et al., 2006) were pre-extracted with 0.007 % digitonin for 5 minutes on ice, supplemented with 4 g YFP-SUMO1, either in cytosol with ATP, or in cytosol pretreated with hexokinase and glucose to deplete ATP. After incubation at 37C, cells were washed, fixed in 4% formaldehyde, 20 mM PIPES pH 6.8, 4 mM EGTA, 1 mM MgCl 2 for 10 min, and processed for immunofluorescence as described in the experimental procedures. Staining was performed with goat  RanBP2 /  goatAlexa 594. Samples were analyzed on a LSM 510 META confocal microscope using a 63x water immersion objective.
Colocalization analysis
Confocal images were scanned with a pixel size of 80x80 nm, Z planes were acquired at 210 nm intervals; images were spectrally unmixed based on recorded spectra from single-colour stained samples processed in parallel. Confocal sections of three cells were background-subtracted and the histograms of the two channels were normalized. Pearson's correlation coefficient and Manders' overlap coefficients were calculated using the JACoP plugin (Bolte and Cordelières, 2006) in ImageJ. For Manders' coefficient, images were thresholded by subtraction. A double RanBP2 stained sample served as positive control to obtain the maximal colocalization that can be achieved under our experimental conditions; randomized RanGAP1 channel images served as negative control. For line profiles, merged confocal image sections converted to RGB were analyzed using the RGB profile plot macro.
